In This Section

Challenges of Academic Drug Discovery in Cancer

Saturday April 04, 2020

11:00 am - 1:00 pm Eastern Time (ET)

Room 15 A

DCP DDD NEU

Chair :

Markos Leggas
University of Kentucky

Michelle Arkin
University of California, San Francisco



This symposium draws on the experiences of academic investigators to highlight their scientific efforts and challenges in academic drug discovery. Presentations feature diverse efforts with topics ranging from the development of new platforms for targeting 'undruggable' proteins, the discovery of cyclin-kinase specific 'degraders' as tools and pharmacological interventions in cancer, the identification and pharmacologic targeting of p97 as a novel cancer target, to the development of dual-kinase inhibitors as a polypharmacologic strategy for overcoming adaptive resistance to therapy in acute myeloid leukemia.

Speakers

Donna Huryn - University of Pittsburgh

Discovery of P97 Modulators - An Emerging Cancer Target

Craig Thomas - National Center for Advancing Translational Sciences (NCATS), NIH

Development of Dual RTK+IRAK Inhibitors as a Means to Overcome Adaptive Resistance in Multiple Cancer Settings

Markos Leggas - University of Kentucky

Drugging the ‘Undruggable’ – ETS Transcription Factor Inhibitors

Michelle Arkin - University of California, San Francisco

Tackling Challenging Drug Targets Using Fragment-Based Ligand Discovery